 |
인쇄하기
취소
|
KFDA announces safety information of pergolide products
The Korea Food and Drug Administration issued a warning letter of the prescribing information for pergolide mesylate (Permax) to inform healthcare professionals of reports of cardiac valvulopathy involving one or more valves in patients receiving pergolide therapy
The U.S. Food and Drug Administration announced on March 29 that manufacturers of pergolide drug products, which are used to trea...
The U.S. Food and Drug Administration announced on March 29 that manufacturers of pergolide drug products, which are used to trea...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.